Your browser doesn't support javascript.
loading
Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator.
Francia, Pietro; Ziacchi, Matteo; Adduci, Carmen; Ammendola, Ernesto; Pieragnoli, Paolo; De Filippo, Paolo; Rapacciuolo, Antonio; Rella, Valeria; Migliore, Federico; Viani, Stefano; Musumeci, Maria Beatrice; Biagini, Elena; Lovecchio, Mariolina; Baldini, Rossella; Falasconi, Giulio; Autore, Camillo; Biffi, Mauro; Cecchi, Franco.
Affiliation
  • Francia P; Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Ziacchi M; Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
  • Adduci C; Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Ammendola E; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Monaldi Hospital, Naples, Italy.
  • Pieragnoli P; Careggi University Hospital, University of Florence, Florence, Italy.
  • De Filippo P; Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Rapacciuolo A; Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
  • Rella V; Department of Cardiovascular, Neural and Metabolic Sciences, IRCCS, Istituto Auxologico Italiano, San Luca Hospital, Milan, Italy.
  • Migliore F; Department of Cardiac, Thoracic Vascular Sciences and Public Health University of Padova, Padova, Italy.
  • Viani S; Second Cardiology Division, Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
  • Musumeci MB; Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Biagini E; Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
  • Lovecchio M; Boston Scientific, Milan, Italy.
  • Baldini R; Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Falasconi G; Campus Clínic, University of Barcelona, Barcelona, Spain.
  • Autore C; IRCCS Humanitas Research Hospital, Milan, Italy.
  • Biffi M; Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Cecchi F; Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
Europace ; 25(9)2023 08 02.
Article in En | MEDLINE | ID: mdl-37724686
ABSTRACT

AIMS:

The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD. METHODS AND

RESULTS:

Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR 0.32; 95%CI 0.15-0.65; P = 0.002) and inappropriate (HR 0.44; 95%CI 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR 0.17; 95%CI 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR 0.64; 95%CI 0.27-1.52; P = 0.309) and mortality (HR 0.74; 95%CI 0.29-1.87; P = 0.521).

CONCLUSION:

Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic / Defibrillators, Implantable Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Europace Journal subject: CARDIOLOGIA / FISIOLOGIA Year: 2023 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic / Defibrillators, Implantable Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Europace Journal subject: CARDIOLOGIA / FISIOLOGIA Year: 2023 Document type: Article Affiliation country: Italy